FrancophonIA/ELRC3.0 huggingface dataset:
English: It must not be used in patients with permanent atrial fibrillation of unknown duration or lasting for more than six months when the doctor has decided not to try to restore normal rhythm.
Slovenian: Ne sme se uporabljati pri bolnikih s trajno atrijsko fibrilacijo z neznanim obdobjem trajanja ali z več kot šestmesečnim trajanjem, če je zdravnik presodil, da ne bo poskušal vzpostaviti normalnega srčnega ritma.
English: The company that makes Multaq must ensure that healthcare professionals who prescribe and dispense the medicine in all Member States are given a ‘prescriber guide'.
Slovenian: Družba, ki izdeluje zdravilo Multaq, mora zagotoviti, da bodo zdravstveni delavci, ki predpisujejo in izdajajo to zdravilo, v vseh državah članicah prejeli napotke za predpisovanje zdravila.
English: The guide will also include information on: when not to use Multaq; medicines that interact with Multaq; the need to monitor the function of the liver, lung, heart and kidneys before and during treatment; and what advice to give to patients on Multaq treatment.
Slovenian: Napotki bodo vsebovali tudi informacije o naslednjih temah: kdaj je uporaba zdravila Multaq odsvetovana; zdravila, ki medsebojno delujejo z zdravilom Multaq; potreba po spremljanju delovanja jeter, pljuč, srca in ledvic pred uvedbo zdravljenja in med njim; ter kakšne nasvete je treba dati bolnikom, ki prejemajo zdravilo Multaq.
English: Other information about Multaq
Slovenian: Druge informacije o zdravilu Multaq
English: Multaq should only be prescribed after alternative treatment options have been considered.
Slovenian: Zdravilo Multaq se lahko predpiše le po tem, ko so bile pretehtane vse druge možnosti zdravljenja.
English: What is Multaq and what is it used for?
Slovenian: Kaj je zdravilo Multaq in za kaj se uporablja?
English: Increased flow of charged particles produces the excessive electrical activity that leads to atrial fibrillation and rapid heart rate.
Slovenian: Povečan pretok nabitih delcev povzroči prekomerno električno dejavnost, ki vodi v atrijsko fibrilacijo in pospešeno bitje srca.
English: Based on the available evidence, the CHMP decided that Multaq's benefits are greater than its risks and recommended that Multaq be given marketing authorisation.
Slovenian: Glede na razpoložljive dokaze je odbor CHMP zaključil, da so koristi zdravila Multaq večje od z njim povezanih tveganj in priporočil, da se zanj izda dovoljenje za promet.
English: Multaq must not be used in patients who have severe problems with their liver or kidneys.
Slovenian: Zdravila Multaq ne smejo uporabljati bolniki s hudimi težavami z jetri ali ledvicami.
English: The study was stopped early because of severe cardiovascular events (such as cardiovascular death or hospitalisation and stroke) in some patients taking Multaq.
Slovenian: Študijo so kmalu prekinili zaradi hudih kardiovaskularnih dogodkov (kot je denimo smrt zaradi kardiovaskularnih zapletov ali hospitalizacija in kap) pri nekaterih bolnikih, ki so jemali zdravilo Multaq.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Multaq have also been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Multaq upoštevati zdravstveni delavci in bolniki, so prav tako vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
English: Atrial fibrillation is when the atria (the upper chambers of the heart) contract irregularly and rapidly, and this abnormality can be short-lasting (paroxysmal) or it can last longer than a few days (persistent).
Slovenian: Atrijska fibrilacija nastopi, kadar se atrija (preddvora srca) neenakomerno in hitro krčita, pri čemer je lahko ta nepravilnost kratkotrajna (paroksizimalna) ali trajajoča nekaj dni (perzistentna).
English: For more information about treatment with Multaq, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Multaq preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Patients who have had previous liver or lung injury following treatment with amiodarone (another antiarrhythmic medicine) must not be given Multaq.
Slovenian: Bolniki, ki so v preteklosti utrpeli poškodbe jeter ali pljuč zaradi zdravljenja z amiodaronom (drugim zdravilom za zdravljenje aritmije), zdravila Multaq ne smejo jemati.
English: Multaq contains the active substance dronedarone.
Slovenian: Zdravilo Multaq vsebuje zdravilno učinkovino dronedaron.
English: The fifth study compared Multaq with placebo in almost 5,000 patients.
Slovenian: V peti študiji so zdravilo Multaq primerjali s placebom pri skoraj 5 000 bolnikih.
English: The fourth study compared Multaq with amiodarone (another medicine used to prevent atrial fibrillation) in 504 patients.
Slovenian: V četrti študiji so zdravilo Multaq primerjali z amiodaronom (drugim zdravilom za preprečevanje atrijske fibrilacije) pri 504 bolnikih.
English: A sixth study (PALLAS) compared Multaq with placebo in patients over 65 years of age with permanent atrial fibrillation and several risk factors.
Slovenian: V šesti študiji (PALLAS) so primerjali zdravilo Multaq s placebom pri bolnikih, starejših od 65 let, s trajno atrijsko fibrilacijo in številnimi dejavniki tveganja.
English: There were six main studies of Multaq in adults who had had atrial fibrillation.
Slovenian: Izvedenih je bilo šest glavnih študij zdravila Multaq pri odraslih z atrijsko fibrilacijo.
English: Multaq was less effective than amiodarone at maintaining normal rhythm: after a year, atrial fibrillation came back or treatment was stopped in 75% of the patients taking Multaq, compared with 59% of the patients receiving amiodarone.
Slovenian: Zdravilo Multaq je bilo manj učinkovito od amiodarona pri vzdrževanju normalnega srčnega ritma: po letu dni se je atrijska fibrilacija ponovila oziroma je bilo zdravljenje prekinjeno pri 75 % bolnikov, ki so jemali zdravilo Multaq, v primerjavi z 59 % bolnikov, ki so prejemali amiodaron.
English: The most common side effects with Multaq (seen in more than 1 patient in 10) are increased blood levels of creatinine (a breakdown product of muscle), a prolonged ‘QTc Bazett' (an alteration of the electrical activity of the heart) and congestive heart failure (a type of heart disease), but this side effect occurred at a similar rate in patients who took placebo in clinical studies.
Slovenian: Najpogostejši neželeni učinki zdravila Multaq (opaženi pri več kot 1 bolniku od 10) so povečane ravni kreatinina (presnovnega produkta mišic), podaljšanje QTc po Bazettu (sprememba električne dejavnosti srca) in kongestivno srčno popuščanje (vrsta srčnega obolenja), pri čemer pa se je ta neželeni učinek v podobnem številu pojavil pri bolnikih, ki so v kliničnih študijah prejemali placebo.
English: Multaq can only be obtained with a prescription and treatment with it should be started and monitored under specialist supervision.
Slovenian: Predpisovanje in izdaja zdravila Multaq je le na recept, zdravljenje z njim pa se lahko uvede in spremlja le po nadzorom zdravnika specialista.
English: The study found that in patients taking Multaq, there were fewer hospital admissions for cardiovascular disorders (problems affecting the heart and blood vessels), particularly those related to atrial fibrillations.
Slovenian: Študija je pokazala, da je bilo med bolniki, ki so jemali zdravilo Multaq, manj hospitalizacij zaradi kardiovaskularnih težav (težav, ki prizadenejo srce in ožilje), zlasti tistih, ki so povezane z atrijsko fibrilacijo.
English: Why is Multaq approved?
Slovenian: Zakaj je bilo zdravilo Multaq odobreno?
English: In September 2011 this indication was restricted to the maintenance of normal heart rhythm in ‘persistent' or ‘paroxysmal' atrial fibrillation after normal heart rhythm has been restored.
Slovenian: Septembra 2011 je bila ta indikacija omejena le na vzdrževanje normalnega srčnega ritma pri perzistentni ali paroksimalni atrijski fibrilaciji po ponovni vzpostavitvi normalnega srčnega ritma.
English: Multaq prevented fibrillation for an average of 116 days compared to 53 days with placebo.
Slovenian: Zdravilo Multaq je preprečevalo fibrilacijo povprečno 116 dni, medtem ko jo je placebo preprečeval 53 dni.
English: What are the risks associated with Multaq?
Slovenian: Kakšna tveganja so povezana z zdravilom Multaq?
English: It is not intended to provide practical advice on how to use Multaq.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: The first three studies, involving, 1,411 patients, found that Multaq was more effective than placebo (a dummy treatment) at preventing atrial fibrillation.
Slovenian: V prvih treh študijah, v katere je bilo vključenih 1 411 bolnikov, so ugotovili, da je zdravilo Multaq pri preprečevanju atrijske fibrilacije učinkovitejše od placeba (zdravila brez zdravilne učinkovine).
English: Multaq should not be given to patients with left ventricular systolic dysfunction (a problem affecting the left side of the heart) or patients who have or have had heart failure (when the heart cannot pump enough blood around the body).
Slovenian: Zdravilo Multaq se ne sme dajati bolnikom s sistolično disfunkcijo levega prekata (težavo, ki prizadene levo stran srca) ali bolnikom, ki imajo trenutno srčno popuščanje ali pa so ga imeli v preteklosti (težavo, pri kateri srce ne more črpati dovolj krvi po telesu).
English: Heart rate was reduced by an average of 11.0 beats per minute in patients taking Multaq compared to 0.7 beats per minute in patients taking placebo.
Slovenian: Srčni utrip se je pri bolnikih, ki so jemali zdravilo Multaq, zmanjšal povprečno za 11,0 utripov na minuto v primerjavi z zmanjšanjem za 0,7 utripa na minuto pri bolnikih, ki so jemali placebo.
English: For the full list of all side effects reported with Multaq, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Multaq, glejte navodilo za uporabo.
English: For practical information about using Multaq, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Multaq naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: Multaq is an antiarrhythmic medicine used to maintain normal heart rhythm in adults whose normal heart rhythm has been restored after a period of paroxysmal or persistent atrial fibrillation.
Slovenian: Zdravilo Multaq je zdravilo proti aritmiji, ki se uporablja za vzdrževanje normalnega srčnega ritma pri odraslih, pri katerih se je normalni srčni ritem ponovno vzpostavil po obdobju paroksizimalne ali perzistentne atrijske fibrilacije.
English: Multaq was originally approved to prevent atrial fibrillation from coming back or to lower the heart rate in adults who have had or have non-permanent atrial fibrillation.
Slovenian: Zdravilo Multaq je bilo prvotno odobreno za preprečevanje ponovitve atrijske fibrilacije ali zniževanje srčnega utripa pri odraslih, ki imajo ali so v preteklosti imeli netrajno atrijsko fibrilacijo.
English: It gave further support for the use of Multaq to maintain normal heart rhythm and to reduce the heart rate.
Slovenian: Izsledki te študije so dodatno podprli uporabo zdravila Multaq za vzdrževanje normalnega srčnega ritma in zniževanje srčnega utripa.
English: The active substance in Multaq, dronedarone, works mainly by blocking channels through which charged particles of potassium flow in and out of the heart muscle cells.
Slovenian: Zdravilna učinkovina v zdravilu Multaq, dronedaron, deluje tako, da zapira kanale, skozi katere potujejo nabiti delci kalija v celice srčne mišice in iz nje.
English: Multaq must not be taken with medicines that can cause torsades de pointes (a type of rapid heart beat), or with dabigatran (a medicine to prevent blood clotting).
Slovenian: Zdravilo Multaq se ne sme jemati skupaj z zdravili, ki lahko sprožijo torsades de pointes (vrsto hitrega srčnega utripa), ali z dabigatranom (zdravilom za preprečevanje krvnih strdkov).
English: The main measure of effectiveness was how long the treatment prevented an attack of atrial fibrillation or the change in the patients' heart rate after two weeks.
Slovenian: Glavno merilo učinkovitosti je bil čas, v katerem je zdravilo Multaq po dveh tednih preprečevalo napad atrijske fibrilacije ali spremembo srčnega utripa.
English: The prescriber guide will help healthcare professionals to use Multaq safety and to select patients for whom it is appropriate.
Slovenian: Napotki za predpisovanje zdravila zdravstvenih delavcem pomagajo pri zagotavljanju varne uporabe tega zdravila in skrbne izbire bolnikov, za katere je to zdravilo primerno.
English: However, more patients taking amiodarone had to stop treatment because of side effects.
Slovenian: Vendar pa je bilo število bolnikov, ki so morali zdravljenje prekiniti zaradi neželenih učinkov večje v skupini, ki je jemala amiodaron.
English: By reducing the flow of potassium through the channels, Multaq slows down contractions in the atria and so prevents fibrillation and lowers the heart rate.
Slovenian: Zdravilo Multaq z zmanjšanjem pretoka kalija skozi te kanale upočasni krčenje atrijev in tako preprečuje fibrilacijo ter znižuje srčni utrip.
English: How is Multaq used?
Slovenian: Kako se zdravilo Multaq uporablja?
English: How does Multaq work?
Slovenian: Kako zdravilo Multaq deluje?
English: Date of first authorisation: 18 January 2016
Slovenian: Datum prve odobritve: 18 januar 2016
English: Your condition will be closely monitored during treatment.
Slovenian: Vaše stanje bodo med zdravljenjem skrbno nadzorovali.
English: The pH is between 7.0 and 8.0.
Slovenian: pH je med 7,0 in 8,0.
English: Inactive vaccines should be used where possible.
Slovenian: Če je mogoče, je treba uporabiti inaktivirano cepivo.
English: *Definition of frequency terms: Very common - ≥10%; Common - >5% and <10%.
Slovenian: * Definicija pogostnosti: Zelo pogosto - > 10 %; Pogosto - > 5 % in < 10 %.
English: Nerviano, Milan Italy
Slovenian: Nerviano, Milano Italija
English: 20014 Nerviano (Milan) Italy
Slovenian: 20014 Nerviano (Milano) Italija
English: Between patient variability in clearance is moderate at 19.3%.
Slovenian: Variabilnost med bolniki v očistku je zmerna, 19,3 %.
English: RO-011171 Bucharest Romania
Slovenian: RO-011171 Bukarešta Romunija
English: Based on the planned date of your infusion of Armisarte and/or on the status of your kidney function, your doctor needs to advise you on which medicines you can take and when you can take them.
Slovenian: Na podlagi načrtovanega datuma vaše infuzije zdravila Armisarte in/ali glede na delovanje vaših ledvic vam mora zdravnik svetovati, katera zdravila lahko jemljete in kdaj jih lahko jemljete.
English: Armisarte may make you feel tired.
Slovenian: Zdravilo Armisarte lahko povzroči, da se boste počutili utrujene.
English: Calculate the dose and the number of Armisarte vials needed.
Slovenian: Preračunajte odmerek in število potrebnih vial zdravila Armisarte.
English: - if you are allergic to pemetrexed or any of the other ingredients of this medicine (listed in section 6).
Slovenian: - če ste alergični na pemetreksed ali na katero koli sestavino tega zdravila (navedeno v poglavju 6).
English: Read all of this leaflet carefully before you start receiving this medicine because it contains important information for you.
Slovenian: Pred začetkom jemanja zdravila, natančno preberite navodilo, ker vsebuje za vas pomembne podatke!
English: Response rate (%) (95 % CI) Stable disease (%)
Slovenian: Stopnja odzivnosti (%) (95 % IZ) Stabilna bolezen (%)
English: This medicinal product must not be mixed with other medicinal products.
Slovenian: To zdravilo se ne sme mešati z drugimi zdravili.
English: Fully supplemented Patients
Slovenian: Bolniki s popolnim bolniki dopolnjevanjem
English: Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicine for pain or inflammation (swelling), such as medicines called “nonsteroidal anti-inflammatory drugs” (NSAIDs), including medicines purchased without a doctor's prescription (such as ibuprofen).
Slovenian: Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katera koli druga zdravila, vključno z zdravili proti bolečinam ali vnetju (oteklinam), denimo zdravila, imenovana “nesteroidna protivnetna zdravila” (NSAID), vključno z zdravili, ki ste jih dobili brez recepta (kot npr. ibuprofen).
English: The dose of Armisarte is 500 milligrams for every square metre of your body's surface area.
Slovenian: Odmerek zdravila Armisarte je 500 miligramov za vsak kvadratni meter površine vašega telesa.
English: Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Slovenian: Podrobne informacije o tem zdravilu so dostopne na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
English: 11 Ion Mihalache Blvd. 011171 Bucharest Romania
Slovenian: 11 Ion Mihalache Blvd. 011171 Bukarešta Romunija
English: Store and transport refrigerated (2°C to 8°C).
Slovenian: Zdravilo shranjujte in prevažajte na hladnem (2°C to 8°C).
English: Your doctor will discuss with you the potential risk of taking Armisarte during pregnancy.
Slovenian: Z zdravnikom se pogovorite o možnem tveganju pri prejemanju zdravila Armisarte v času nosečnosti.
English: Upon recovery patients should be retreated using the guidelines in Tables 1, 2 and 3, which are applicable for pemetrexed used as a single agent or in combination with cisplatin.
Slovenian: Po okrevanju bolnike ponovno zdravimo z uporabo smernic v Preglednicah 1, 2 in 3, ki veljajo za pemetreksed, če jo uporabljamo kot edino učinkovino ali v kombinaciji s cisplatinom.
English: This routinely involves blood tests, including checks on your liver and kidney function.
Slovenian: To rutinsko vključuje preiskave krvi, vključno s preverjanjem delovanja vaših jeter in ledvic.
English: Other medicines and Armisarte
Slovenian: Druga zdravila in zdravilo Armisarte
English: 75% of previous dose
Slovenian: 75 % predhodnega odmerka
English: **In the pemetrexed/cisplatin arm, randomized and treated (N=225) and fully supplemented (N=167)
Slovenian: **V veji zdravljenja s pemetreksedom/cisplatinom, randomizirani in zdravljeni (N = 225) ter s popolnim dopolnjevanjem (N = 167).
English: This medicine is for single use only; any unused solution must be disposed of in accordance with local requirements.
Slovenian: To zdravilo je namenjeno samo enkratni uporabi, morebitno neporabljeno raztopino je treba odstraniti v skladu z lokalnimi predpisi.
English: 75% of previous dose (both pemetrexed and cisplatin)
Slovenian: 75 % predhodnega odmerka (obeh pemetrekseda in cisplatina)
English: Before each infusion you will have samples of your blood taken to evaluate if you have sufficient kidney and liver function and to check that you have enough blood cells to receive Armisarte.
Slovenian: Pred vsako infuzijo vam bomo odvzeli vzorce krvi za vrednotenje delovanja vaših ledvic in jeter ter oceno, ali imate dovolj krvnih celic za prejemanje zdravila Armisarte.
English: Trometamol is incompatible with cisplatin resulting in degradation of cisplatin.
Slovenian: Trometamol je inkompatibilen s cisplatinom in povzroči razgradnjo cisplatina.
English: At the time of this final survival analysis, 28.7% of patients were alive or lost to follow up on the pemetrexed arm versus 21.7% on the placebo arm.
Slovenian: V času te končne analize preživetja je bilo živih ali ni bilo na voljo za nadaljnje spremljanje 28,7 % bolnikov v kraku pemetrekseda v primerjavi z 21,7 % v kraku s placebom.
English: Contents of the pack and other information What Armisarte contains
Slovenian: Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Armisarte
English: The pharmacokinetic properties of pemetrexed following single-agent administration have been evaluated in 426 cancer patients with a variety of solid tumours at doses ranging from 0.2 to 838 mg/m2 infused over a 10 minute period.
Slovenian: Farmakokinetične lastnosti pemetrekseda po dajanju ene učinkovine so vrednotili pri 426 bolnikih z različnimi malignimi trdnimi tumorji v razponu odmerkov od 0,2 do 838 mg/m2, infundiranih v 10 minutah.
English: < 1/100), Rare (≥ 1/10,000 to < 1/1,000), Very rare (< 1/10,000) and not known (cannot be estimated from available data).
Slovenian: Pogostnosti so določene kot: zelo pogosto (≥ 1/10), pogosto (≥ 1/100 do < 1/10), občasno (≥1/1.000 do < 1/100), redko (≥ 1/10.000 do < 1/1.000), zelo redko (< 1/10.000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
English: Any unused medicinal product or waste material must be disposed of in accordance with local requirements.
Slovenian: Neuporabljeno zdravilo ali odpadke je treba zavreči v skladu z lokalnimi zahtevami.
English: Pemetrexed N=265
Slovenian: Pemetreksed N = 265
English: Name and address of the manufacturers responsible for batch release PLIVA CROATIA Ltd.
Slovenian: Ime in naslov izdelovalca (izdelovalcev), odgovornega (odgovornih) za sproščanje serij PLIVA CROATIA Ltd.
English: If you have been recently vaccinated, please tell your doctor, as this can possibly cause bad effects with Armisarte.
Slovenian: Če ste bili nedavno cepljeni, prosimo, povejte to zdravniku saj lahko to ob jemanju zdravila Armisarte povzroča škodljive učinke.
English: When using Armisarte in combination with cisplatin:
Slovenian: Kadar uporabljamo zdravilo Armisarte v kombinaciji s cisplatinom:
English: ****Combined term includes increased serum/blood creatinine, decreased glomerular filtration rate, renal failure and renal/genitourinary- other.
Slovenian: **** Skupni izraz vključuje povišan kreatinin v serumu/krvi, znižano stopnjo glomerulne filtracije, ledvično odpoved in ledvice/sečila - drugo.
English: Armisarte is a medicine used in the treatment of cancer.
Slovenian: Zdravilo Armisarte uporabljamo pri zdravljenju raka.
English: If you currently have or have previously had problems with your kidneys, talk to your doctor or hospital pharmacist as you may not be able to receive Armisarte.
Slovenian: Če imate ali ste imeli težave z ledvicami, se pogovorite z zdravnikom ali bolnišničnim farmacevtom, ker morda ne boste mogli prejeti zdravila Armisarte.
English: The use of Armisarte should be avoided during pregnancy.
Slovenian: Uporabi zdravila Armisarte med nosečnostjo se izogibamo.
English: Cisplatin is also given by infusion into one of your veins, and is given approximately 30 minutes after the infusion of Armisarte has finished.
Slovenian: Cisplatin tudi dajemo v obliki infuzije v veno, približno 30 minut po zaključku infuzije zdravila Armisarte.
English: Progression free survival (months)
Slovenian: Preživetje brez napredovanja (meseci)
English: Pharmacotherapeutic group: antineoplastic agents, folic acid analogues, ATC code: L01BA04.
Slovenian: Farmakoterapevtska skupina: Analogi folne kisline, Oznaka ATC: L01BA04
English: If you have an accumulation of fluid around your lungs, your doctor may decide to remove the fluid before giving you Armisarte.
Slovenian: Če se vam okrog pljuč nabira tekočina, se bo zdravnik morda odločil tekočino pred dajanjem zdravila Armisarte odstraniti.
English: Common Pain Oedema Renal Disorders Common Renal disorders**** Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CTCAE = Common Terminology Criteria for Adverse Event; NCI = National Cancer Institute; SGOT=serum glutamic oxaloacectic aminotransferase; SGPT=serum glutamic pyruvic aminotransferase.
Slovenian: Okrajšave: ALT = alaninska aminotransferaza; AST = aspartatna aminotransferaza; CTCAE = običajni terminološki kriteriji za neželene učinke; NCI = nacionalni inštitut za rakava obolenja; SGOT = serumska glutamat oksalocetna aminotransferaza; SGPT = serumska glutamat piruvična aminotransferaza.
English: ANNEX II
Slovenian: PRILOGA IV